Home Newsfeeds Needham Maintains Buy on Unity Software, Raises Price Target to $44

Needham Maintains Buy on Unity Software, Raises Price Target to $44

Needham analyst Bernie McTernan maintains Unity Software (NYSE:U) with a Buy and raises the price target from $35 to $44.

byBenzinga Newsdesk

February 23, 2023

1 minute read

Needham analyst Bernie McTernan maintains Unity Software (NYSE:U) with a Buy and raises the price target from $35 to $44.

Cellectis Presents Updated Clinical And Translational Data On BALLI-01 At The European Hematology Association 2023

By Happy Mohamed

June 9, 4:31 PM

Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, presented today updated clinical

CLLS

News

RF Acquisition Corp. Announces Receipt Of Nasdaq Listing Delinquency Letter

By Happy Mohamed

April 25, 4:06 PM

RF Acquisition Corp. (NASDAQ:RFACU, RFAC, RFACW, RFACR)))) (the "Company") announced today that on April 19, 2023 it received a notice ("Notice") from the Listing Qualifications Department of

RFAC

Senior Administration Official Says U.S. Sticking To Position That U.S. Will Not Provide Tanks To Ukraine At This Time

By Benzinga Newsdesk

January 20, 12:29 PM

- Reuters

RSX

FDA
News

Tarsus To Present Saturn-2 Pivotal Phase 3 Trial Data And Saturn-1 Extension Study Long-term Safety Data Evaluating TP-03 For The Treatment Of Demodex Blepharitis At Upcoming Eye Care Meetings

By Benzinga Newsdesk

September 27, 12:01 PM

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that the

TARS

Needham Maintains Buy on Unity Software, Raises Price Target to $44

Related Posts

Cellectis Presents Updated Clinical And Translational Data On BALLI-01 At The European Hematology Association 2023

RF Acquisition Corp. Announces Receipt Of Nasdaq Listing Delinquency Letter

Senior Administration Official Says U.S. Sticking To Position That U.S. Will Not Provide Tanks To Ukraine At This Time

Tarsus To Present Saturn-2 Pivotal Phase 3 Trial Data And Saturn-1 Extension Study Long-term Safety Data Evaluating TP-03 For The Treatment Of Demodex Blepharitis At Upcoming Eye Care Meetings